Table 3.

Participants screened for cervical cancer and the concordance rates

Phase	No VIA screened	No VIA positive	Reviewer diagnosis/case finder	Positive concordance (%)	Reviewer diagnosis/case finder	Negative concordance (%)
Pilot phase (December 2019–June 2020)	182	9	NA	NA	NA	NA
Pre-AVIVA Phase 1 (July 2020–October 2020)	2892	117	9/35 Sample*	25.71	N/A	N/A
Post-VIVA Phase 1 (November 2020–March 2021)	5184	432	65/152 Sample†	42.76	115/144 Sample†	79.86
Phase 2 (April 2021–April 2022)	16 465	907	70/180 Sample†	38.89	671/722 Sample†	92.94
Phase 3 (May 2022– June 2022)	4539	144	5/12 Sample†	41.67	172/180 Sample†	95.56

*Reviewed by gynaecologist on-site.

†Reviewed by gynaecologist using AVIVA.

AVIVA, APIN developed VIA Visual Application; NA, not available; VIA, visual inspection with acetic acid.